Clinical trials: Prostate
Prostate Cancer, Pneumoperitoneum
Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies
The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.
- Trial name
- NCT02114164
- Testing
- AirSeal System, Standard Endopath
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- OhioHealth
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).
- Trial name
- REZUM (NCT01912339)
- Testing
- Rezum System, Rigid Cystoscopy
- Where
- 15 sites in United States
- Volunteers
- 197 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
This was a Phase 1, open-label, fixed-dose study of immunization with the NY-ESO-1 protein combined with CpG 7909 as an adjuvant in patients with histopathologically confirmed, high-risk Stage D1 or advanced prostate cancer.
- Trial name
- NCT00292045
- Testing
- NY-ESO-1 protein/CpG 7909
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 15 people
- Sponsor
- Ludwig Institute for Cancer Research
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Neuroendocrine Tumors, Prostate Cancer
Dual-Tracer Theranostic PET
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging…
- Trial name
- NCT05680675
- Testing
- Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE PET/CT Exam, Single-Tracer Ga68-DOTATATE PET/CT Exam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Utah
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Benign Prostatic Hyperplasia, Enlarged Prostate
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate…
- Trial name
- NCT01139762
- Testing
- Tadalafil, Finasteride
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 696 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Phase I/II Hypofractionated Radiotherapy for Prostate Cancer
The purpose of this study is to examine the clinical feasibility of using Intensity-modulated radiation therapy (IMRT) combined with daily pretreatment prostate localization to deliver increasingly hypofractionated treatment…
- Trial name
- NCT00214097
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 347 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Trial of Community Health Worker-led Decision Coaching
Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the U.S. This randomized trial will evaluate the efficacy of a Community Health Worker-led decision coaching…
- Trial name
- NCT03726320
- Testing
- Education Counseling Session for PSA Screening, General Health Counseling Coaching
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Healthy
Adherence Dynamics for Whole Food Interventions in African-American Men
The purposes of this study are to explore the dynamics of adherence, using a simple whole food intervention strategy, both prior to and during the intervention period and to identify nutrient shifts in self-selected diets and to…
- Trial name
- DAPH (NCT01408459)
- Testing
- Tomato Product, Control
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Prostate Cancer
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a…
- Trial name
- NCT01057810
- Testing
- Ipilimumab
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 837 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer, Erectile Dysfunction
Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy
This research study aims to explore the effectiveness of human erythropoietin versus placebo in promoting the recovery of erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for…
- Trial name
- ERECT (NCT00737893)
- Testing
- Erythropoietin (EPO)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University
Prostate Cancer
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- SHIP (NCT02146833)
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Karyopharm Therapeutics Inc
Bladder Outlet Obstruction
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
This study is a prospective randomized, open label, controlled, double arm, post-marketing study to compare the treatment efficacy of first-line antimuscarinics and α-blockers monotherapy for men with moderate to severe lower…
- Trial name
- NCT01661621
- Testing
- Detrusitol 4 mg QD, Doxazosin 4 mg QD
- Where
- Taiwan
- Volunteers
- 395 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Melanoma, Prostate Cancer
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Trial name
- NCT01650350
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brown University
Prostate Cancer
Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy
This study is designed to assess the effect of catheter size on postoperative catheter pain, urinary continence, urinary flow rates, post void residuals, International Prostate Symptom Scores (IPSS), and Quality of Life (QoL)…
- Trial name
- NCT04098809
- Testing
- 16 French urinary catheter, 20 French urinary catheter
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Benaroya Research Institute
Prostate Cancer Non-Metastatic, Castration-Resistant
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
- Trial name
- ARAMIS (NCT02200614)
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 404 sites in United States, Argentina and 34 more
- Volunteers
- 1,509 people
- Sponsor
- Bayer
Prostate Cancer
Digoxin for Recurrent Prostate Cancer
The purpose of this study is to assess the effectiveness of dioxin on prohibiting prostate cancer progression as measured by PSADT (prostate-specific antigen doubling time).
- Trial name
- NCT01162135
- Testing
- Digoxin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy
The study population will be 80 adult men who have been diagnosed with prostate cancer who are scheduled to have their prostate surgically removed at either the Medical University of South Carolina (MUSC) or the Ralph H.
- Trial name
- NCT02726113
- Testing
- cholecalciferol
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medical University of South Carolina